company background image
EX1 logo

Exopharm ASX:EX1 Stock Report

Last Price

AU$0.011

Market Cap

AU$4.8m

7D

0%

1Y

-81.7%

Updated

30 Dec, 2023

Data

Company Financials

EX1 Stock Overview

Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia.

EX1 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Exopharm Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Exopharm
Historical stock prices
Current Share PriceAU$0.011
52 Week HighAU$0.079
52 Week LowAU$0.008
Beta1.24
11 Month Change0%
3 Month Change10.00%
1 Year Change-81.67%
33 Year Change-98.07%
5 Year Change-97.68%
Change since IPO-97.88%

Recent News & Updates

Recent updates

Will Exopharm (ASX:EX1) Spend Its Cash Wisely?

May 27
Will Exopharm (ASX:EX1) Spend Its Cash Wisely?

Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?

Oct 20
Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?

Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?

Jul 02
Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?

Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?

Apr 03
Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?

Shareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 188%

Feb 09
Shareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 188%

Shareholder Returns

EX1AU BiotechsAU Market
7D0%-0.01%-1.2%
1Y-81.7%16.7%8.6%

Return vs Industry: EX1 underperformed the Australian Biotechs industry which returned 10% over the past year.

Return vs Market: EX1 underperformed the Australian Market which returned 9.6% over the past year.

Price Volatility

Is EX1's price volatile compared to industry and market?
EX1 volatility
EX1 Average Weekly Movementn/a
Biotechs Industry Average Movement11.3%
Market Average Movement8.2%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market3.2%

Stable Share Price: EX1 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine EX1's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201350Ian Dixonexopharm.com

Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company’s technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine.

Exopharm Limited Fundamentals Summary

How do Exopharm's earnings and revenue compare to its market cap?
EX1 fundamental statistics
Market capAU$4.83m
Earnings (TTM)-AU$7.13m
Revenue (TTM)AU$3.39m

1.4x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EX1 income statement (TTM)
RevenueAU$3.39m
Cost of RevenueAU$3.36m
Gross ProfitAU$28.17k
Other ExpensesAU$7.16m
Earnings-AU$7.13m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.016
Gross Margin0.83%
Net Profit Margin-210.14%
Debt/Equity Ratio37.2%

How did EX1 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.